Literature DB >> 6883710

Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography.

B G Wolthers, M Volmer, J van der Molen, B J Koopman, A E de Jager, R J Waterreus.   

Abstract

By means of capillary gas chromatography urine samples of patients with cerebrotendinous xanthomatosis (CTX) were investigated before and during treatment by oral administration of chenodeoxycholic acid. The occurrence of various conjugated bile alcohols, presumably glucuronides, was demonstrated, the major compound being 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha, 23 xi, 25-pentol. In the bile acid fraction norcholic acid and hydroxycholic acid were shown to be present in considerable amounts. In this way the presence of CTX can be demonstrated conclusively. After chenodeoxycholic acid therapy the excretion of both abnormal bile acids as well as of bile alcohols rapidly decreased within a few weeks, showing the effectiveness of the treatment. By early discovery and subsequent therapy it may be possible to prevent the onset of the detrimental symptoms such as mental deficiency, caused by the accumulation of cholestanol and cholesterol in CTX patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883710     DOI: 10.1016/0009-8981(83)90352-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  Paediatric cerebrotendinous xanthomatosis.

Authors:  R A Wevers; J R Cruysberg; A F Van Heijst; F S Janssen-Zijlstra; W O Renier; B G Van Engelen; J J Tolboom
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat.

Authors:  F Kuipers; M Enserink; R Havinga; A B van der Steen; M J Hardonk; J Fevery; R J Vonk
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 3.  Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid.

Authors:  M Donaghy; R H King; R O McKeran; M S Schwartz; P K Thomas
Journal:  J Neurol       Date:  1990-06       Impact factor: 4.849

4.  Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid.

Authors:  H Ichimiya; H Nazer; T Gunasekaran; P Clayton; J Sjövall
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

5.  Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26.

Authors:  G Salen; S Shefer; G S Tint; G Nicolau; B Dayal; A K Batta
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

6.  Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX).

Authors:  P H Pop; E Joosten; A van Spreeken; A Gabreëls-Festen; H Jaspar; H ter Laak; A Vos
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

7.  Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.

Authors:  B J Koopman; B G Wolthers; J C van der Molen; W van der Slik; R J Waterreus; A van Spreeken
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 8.  Inborn errors of bile acid metabolism.

Authors:  P T Clayton
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

9.  A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.

Authors:  S Skrede; I Björkhem; M S Buchmann; G Hopen; O Fausa
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

10.  The effectiveness of correcting abnormal metabolic profiles.

Authors:  Peter Theodore Clayton
Journal:  J Inherit Metab Dis       Date:  2019-07-17       Impact factor: 4.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.